source
- Excluding orphan drugs from Medicare pricing pilots could erase most savings, analysis showsA Harvard researcher has calculated that removing rare disease treatments from two Medicare pilot programs-GLOBE and GUARD-would dramatically cut the projected cost savings. The pilots are designe…
- Attovia Therapeutics raises $289 million in IPO to fund anti-itch drug developmentAttovia Therapeutics completed an initial public offering that generated $289 million in gross proceeds. The company sold 17 million shares at $17 each, exceeding its original target of $182.4 mill…